Mode
Text Size
Log in / Sign up

Multi-target therapies may address combined hypertension and dyslipidemia pathophysiologyMulti-Target Therapies May Address Combined Hypertension and High Cholesterol

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider multi-target therapy combining RAAS inhibitors, statins, PCSK9 inhibitors, SGLT2 inhibitors, and GLP-1 agonists for hypertension and dyslipidemia, but await clinical trial validation.

This systematic review explores the synergistic mechanisms linking hypertension and dyslipidemia in cardiovascular pathogenesis. The authors identify key pathways including the RAAS/PPAR axis, AMPK/SIRT1 signaling, and NLRP3 inflammasome activation that contribute to vascular damage, endothelial dysfunction, oxidative stress, chronic inflammation, and atherosclerosis. They propose that multi-target therapies combining RAAS inhibitors, statins, PCSK9 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists may offer synergistic benefits by addressing these interconnected pathways.

The review does not report pooled effect sizes, sample sizes, or specific clinical outcomes. Instead, it provides a mechanistic framework for precision-based therapeutic strategies. The authors emphasize the need for a precision medicine approach to tailor combinations of these drug classes based on individual patient pathophysiology.

Limitations are not explicitly reported, but the review does not present clinical trial data on the efficacy or safety of specific drug combinations. The findings are hypothesis-generating and should be interpreted cautiously. While the mechanistic rationale is compelling, clinical validation through well-designed trials is needed before these multi-target strategies can be recommended in practice.

How this fits prior evidence

This systematic review extends prior coverage by providing a mechanistic framework for combining antihypertensive and lipid-lowering therapies. Previous findings showed that SGLT2 inhibitors provide robust benefits in heart failure, and evolocumab reduces MACE by 29% in patients with high BMI. The current review suggests that multi-target strategies may leverage these individual benefits through shared pathways like AMPK/SIRT1 and NLRP3, potentially addressing gaps in combined hypertension and dyslipidemia management. However, unlike the prior trial-level evidence, this review does not provide clinical outcomes for specific combinations.

Researchers reviewed how high blood pressure and high cholesterol work together to damage the heart. They found that these two conditions often share common biological pathways, such as inflammation and oxidative stress. When they occur together, they can lead to more significant vascular damage than if only one condition were present.

The review highlights several types of medications that target different parts of this process. These include RAAS inhibitors, statins, PCSK9 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. Using these multi-target strategies could help doctors create more precise treatment plans for patients dealing with both conditions simultaneously.

It is important to note that this review looks at the biological mechanisms of these drugs rather than testing specific combinations in clinical trials. Because there is no new trial data on drug interactions, you should talk to your doctor about which combination of medications is safest and most effective for your specific health needs.

What this means for you:
Multi-target therapies may help manage the combined effects of high blood pressure and high cholesterol levels.

Common questions

How do high blood pressure and high cholesterol affect the heart together?

When hypertension and dyslipidemia occur together, they share biological pathways like inflammation and oxidative stress. This interplay can lead to increased cardiovascular damage, including issues with vessel function and the buildup of plaque in the arteries.

What types of medications are used for these conditions?

The review identifies several classes of medication that target different pathways: RAAS inhibitors, statins, PCSK9 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists. These can be used in a multi-target strategy to address the combined effects of high blood pressure and cholesterol.

Is it safe to take multiple types of heart medications at once?

The review discusses the potential for multi-target therapies but does not provide specific clinical trial data on the safety or effectiveness of combining these drugs. You should consult your doctor to determine the safest treatment plan for your specific health profile.

Study Details

Study typeSystematic review
EvidenceLevel 1
PublishedJun 2026
View Original Abstract ↓
Cardiovascular disease (CVD) remains the foremost cause of global mortality. Hypertension and dyslipidemia, frequently coexisting, exert synergistic effects that substantially elevate CVD risk via interconnected molecular pathways. This review systematically examines the synergistic mechanisms underlying their combined contribution to CVD progression, with a focus on key pathways such as the RAAS/PPAR axis, AMPK/SIRT1 signaling, and NLRP3 inflammasome activation. We highlight how their interplay disrupts endothelial function, aggravates oxidative stress, and promotes chronic inflammation, thereby causing vascular damage and atherosclerosis. Furthermore, we examine emerging targeted therapies, including the combination of RAAS inhibitors with statins, PCSK9 inhibitors, as well as newer agents such as SGLT2 inhibitors and GLP-1 receptor agonists. These approaches represent promising multi-target strategies for improving clinical outcomes. Ultimately, this review underscores the need for a precision medicine framework that addresses the synergistic pathophysiology of hypertension and dyslipidemia, paving the way for personalized, pathway-integrated interventions aimed at restoring metabolic-vascular homeostasis rather than merely treating disease.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.